Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.

Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, Montravers F.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):943-66. doi: 10.1007/s00259-013-2342-x. Epub 2013 Feb 16. Review.

2.

Role of (18) F-FDOPA PET/CT imaging in endocrinology.

Santhanam P, Taïeb D.

Clin Endocrinol (Oxf). 2014 Dec;81(6):789-98. doi: 10.1111/cen.12566. Epub 2014 Sep 1. Review.

PMID:
25056984
3.

18F-fluorodihydroxyphenylalanine PET/CT in patients with neuroendocrine tumors of unknown origin: relation to tumor origin and differentiation.

Imperiale A, Rust E, Gabriel S, Detour J, Goichot B, Duclos B, Kurtz JE, Bachellier P, Namer IJ, Taïeb D.

J Nucl Med. 2014 Mar;55(3):367-72. doi: 10.2967/jnumed.113.126896. Epub 2013 Dec 16.

5.

Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.

King KS, Chen CC, Alexopoulos DK, Whatley MA, Reynolds JC, Patronas N, Ling A, Adams KT, Xekouki P, Lando H, Stratakis CA, Pacak K.

J Clin Endocrinol Metab. 2011 Sep;96(9):2779-85. doi: 10.1210/jc.2011-0333. Epub 2011 Jul 13.

6.

Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.

Becherer A, Szabó M, Karanikas G, Wunderbaldinger P, Angelberger P, Raderer M, Kurtaran A, Dudczak R, Kletter K.

J Nucl Med. 2004 Jul;45(7):1161-7.

7.

Imaging of neuroendocrine tumors.

Rufini V, Calcagni ML, Baum RP.

Semin Nucl Med. 2006 Jul;36(3):228-47. Review.

PMID:
16762613
8.

What is currently the best radiopharmaceutical for the hybrid PET/CT detection of recurrent medullary thyroid carcinoma?

Slavikova K, Montravers F, Treglia G, Kunikowska J, Kaliska L, Vereb M, Talbot JN, Balogova S.

Curr Radiopharm. 2013 Jun 6;6(2):96-105. Review.

PMID:
23745775
9.

Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.

Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Højgaard L, Kjaer A.

J Nucl Med. 2010 May;51(5):704-12. doi: 10.2967/jnumed.109.069765. Epub 2010 Apr 15.

10.

Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.

Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM.

Eur Radiol. 2016 Mar;26(3):900-9. doi: 10.1007/s00330-015-3882-1. Epub 2015 Jul 12.

PMID:
26162577
11.

18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors.

Minn H, Kemppainen J, Kauhanen S, Forsback S, Seppänen M.

PET Clin. 2014 Jan;9(1):27-36. doi: 10.1016/j.cpet.2013.08.013. Epub 2013 Oct 2. Review.

PMID:
25029931
12.

Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?

Montravers F, Grahek D, Kerrou K, Ruszniewski P, de Beco V, Aide N, Gutman F, Grangé JD, Lotz JP, Talbot JN.

J Nucl Med. 2006 Sep;47(9):1455-62.

13.

Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.

Hicks RJ.

Cancer Imaging. 2010 Oct 4;10 Spec no A:S83-91. doi: 10.1102/1470-7330.2010.9007. Review.

14.

Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.

Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G.

Eur J Nucl Med. 1998 Jan;25(1):79-83.

PMID:
9396878
15.

Nuclear medicine imaging of neuroendocrine tumours.

Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A.

Ann Oncol. 2001;12 Suppl 2:S51-61. Review.

PMID:
11762353
16.

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.

Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, Reznek R, Monson JP, Besser GM, Foley R, Britton KE, Grossman AB.

J Clin Endocrinol Metab. 2001 Feb;86(2):895-902.

PMID:
11158063
17.

Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.

Toumpanakis C, Kim MK, Rinke A, Bergestuen DS, Thirlwell C, Khan MS, Salazar R, Oberg K.

Neuroendocrinology. 2014;99(2):63-74. doi: 10.1159/000358727. Epub 2014 Jan 21. Review.

18.

6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.

Fottner C, Helisch A, Anlauf M, Rossmann H, Musholt TJ, Kreft A, Schadmand-Fischer S, Bartenstein P, Lackner KJ, Klöppel G, Schreckenberger M, Weber MM.

J Clin Endocrinol Metab. 2010 Jun;95(6):2800-10. doi: 10.1210/jc.2009-2352. Epub 2010 Apr 6.

PMID:
20371665
19.

Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.

Treglia G, Castaldi P, Villani MF, Perotti G, de Waure C, Filice A, Ambrosini V, Cremonini N, Santimaria M, Versari A, Fanti S, Giordano A, Rufini V.

Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):569-80. doi: 10.1007/s00259-011-2031-6. Epub 2012 Jan 6.

PMID:
22223169
20.

Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.

Jacob T, Grahek D, Younsi N, Kerrou K, Aide N, Montravers F, Balogova S, Colombet C, De Beco V, Talbot JN.

Eur J Nucl Med Mol Imaging. 2003 Sep;30(9):1266-9. Epub 2003 Jul 10.

PMID:
12856157

Supplemental Content

Support Center